PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 15 | 2 | 116-119
Article title

Effects of L-Arginine Supplementation on Blood Pressure Reduction Pre-, Peri-, and Post-Cardiovascular Stimulus in Hypertensive Subjects with Different Angiotensin-Converting-Enzyme Genotypes

Content
Title variants
Languages of publication
EN
Abstracts
EN
Purpose. The present study investigated whether L-arginine supplementation reduces blood pressure (BP) in hypertensive subjects with different ACE genotypes. Methods. Eight male hypertensive patients received L-arginine (2 or 4 g/day) or a placebo for a period of 4 days prior an exercise test. Statistical analysis consisted of one-way analysis of variance. Results. L-arginine supplementation induced a statistically significant (p ⋋ 0.05) reduction in systolic BP measured during rest (reductions of 7.8% and 12.3% with 2 and 4 g/day, respectively), exercise (reductions of 11.8% and 10.4% with 2 and 4 g/day, respectively), and recovery (reductions of 11.7% and 10.7% with 2 and 4 g/day, respectively). The observed magnitude of BP reduction suggests an association with ACE polymorphism; a larger effect was seen with the II and DI genotypes compared with the DD genotype (II: 121 mmHg and DI: 133 mmHg vs. DD: 144 mmHg). Conclusions. The results showed that L-arginine supplementation at low doses was efficient in reducing BP and that vasodilator actions that occurred through the secretion of nitric oxide might be ACE genotype dependent.
Publisher
Journal
Year
Volume
15
Issue
2
Pages
116-119
Physical description
Dates
online
15 - 8 - 2014
accepted
23 - 4 - 2014
received
8 - 4 - 2013
References
  • 1. Siani A., Pagano E., Iacone R., Iacoviello L., Scopacasa F., Strazzullo P., Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens, 2000, 13 (5), 547–551, doi: 10.1016/S0895-7061(99)00233-2.[Crossref]
  • 2. Stojanovic T., Gröne H.J., Gieseler R.K., Klanke B., Schlemminger R., Tsikas D. et al., Enhanced renal allo-graft rejection by inhibitors of nitric oxide synthase: A non-immunologic influence on alloreactivity. Laboratory Investigation, 1996, 74, 496–512.
  • 3. Cambien F., Costerousse O., Tiret L., Poirier O., Lecerf L., Gonzales M.F. et al., Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation, 1994, 90, 669-676. doi: 10.1161/01.CIR.90.2.669.[Crossref]
  • 4. Soubrier F., Alhenc-Gelas F., Hubert C., Allegrini J., John M., Tregear G. et al., Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 9386–9390.
  • 5. Jalil J.E., Piddo A.M., Cordova S., Chamorro G., Braun S., Jalil R. et al., Prevalence of the angiotensin I-converting enzyme insertion/deletion polymorphism, plasma ACE activity and left ventricular mass in normotensive Chilean population. Am J Hypertens, 1999, 12 (7), 697–704, doi: 10.1016/S0895-7061(99)00040-0.[Crossref]
  • 6. Hernandez D., De La Rosa A., Barragan A., Barrios Y., Salido E., Torres A. et al., The ACE/DD genotype is associated with the extent of exercise-induced left ventricular growth in endurance athletes. J Am Coll Cardiol, 2003, 42 (3), 527–532, doi: 10.1016/S0735-1097(03)00642-9.[Crossref]
  • 7. Chobanian A.V., Bakris G.L., Black H.R., Green W.C.L.A., Izzo J.L., Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension, 2003, 42, 1206–1252, doi: 10.1161/01.HTP.0000107251.49515.c2.[Crossref]
  • 8. Kline G.M., Porcari J.P., Hintermeister R., Freedson P.S., Ward A., Mccarron R.F. et al., Estimation of VO2max from a one-mile track walk, gender, age, and body weight. Med Sci Sport Exerc, 1987, 19, 253–259.
  • 9. Lindpaintner K., Pfeffer M.A., Kreutz R., Stampfer M.J., Grodstein F., Lamotte F. et al., A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med, 1995, 332, 706 –711, doi: 10.1056/N EJM199503163321103.[Crossref]
  • 10. Brown N.J., Blais C. Jr., Gandhi S.K., Adam A., ACE insertion/deletion genotype affects bradykinin metabolism. J Cardiovasc Pharmacol, 1998, 32 (3), 373–377.[Crossref]
  • 11. Maiorana A., O’Driscoll G., Dembo L., Cheetham C., Goodman C., Taylor R. et al., Effect of aerobic and resistance exercise training on vascular function in heart failure. Am J Physiol, 2000, 279 (4), 1999–2005.
  • 12. Maiorana A., O’Driscoll G., Taylor R.R., Green D.J., Exercise and the nitric oxide vasodilator system. Sports Med, 2003, 33 (14), 1013–1035, doi: 10.2165/00007256-200333140-00001.[Crossref]
  • 13. Kobayashi N., Tsuruya Y., Iwasawa T., Ikeda N., Hashimoto S., Yasu T. et al., Exercise training in patients with chronic heart failure improves endothelial function predominantly in the trained extremities. Circ J, 2003, 67 (6), 505–510, doi: 10.1253/circj.67.505.[Crossref]
  • 14. Hosokawa S., Hiasa Y., Takahashi T., Itoh S., Effect of regular exercise on coronary endothelial function in patients with recent myocardial infarction. Circ J, 2003, 67 (3), 221–224, doi: 10.1253/circj.67.221.[Crossref]
  • 15. Hambrecht R., Wolf A., Gielen S., Linke A., Hofer J., Erbs S. et al., Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med, 2000, 342, 454–460, doi: 10.1056/NEJM200002 173420702.[Crossref]
  • 16. Lüscher T.F., Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension? Am J Hypertens, 1990, 3 (4), 317–330, doi: 10.1093/ajh/ 3.4. 317.[Crossref]
  • 17. Daemen M.J., Lombardi D.M., Bosman F.T., Schwartz S.M., Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res, 1991, 68 (2), 450–456, doi: 10.1161/01.RES.68.2.450.[Crossref]
  • 18. Vanhontte P.M., Boulanger C.M., Illiano S.C., Nagao T., Vidal M., Mombouli J.V., Endothelium-dependent effects of converting enzyme inhibitors. J Cardiovasc Pharmacol, 1993, 22 (Suppl. 5), S10–16.
  • 19. He S.W., Huang H.W., Tan S.Q., Fu X., Su L.L., Peng D.X. et al., Influence of angiotensin-converting enzyme insertion/deletion polymorphism on nitric oxide production in hypertensives and hypercholesterolaemics. J Clin Pharm Ther, 2011, 36 (2), 187–193, doi:10.1111/j.1365-2710.2010.01176.x.[Crossref][WoS]
  • 20. Jabecka A., Ast J., Bogdaski P., Drozdowski M., Pawlak-Lemaska K., Cielewicz A.R. et al., Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethy lar gi nine, L-citruline, L-arginine and antioxidant status. Eur Rev Med Pharmacol Sci, 2012, 16 (12), 1665–1674.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_humo-2014-0012
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.